Immix Biopharma, Inc. IMMX
Updated: 10 Aug 2026
No signal published yet
We already track Immix Biopharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Immix Biopharma, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immix Biopharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 22, 2026, Immix Biopharma closed an underwritten public offering of common stock, raising approximately $140.7 million in net proceeds. The funds are earmarked to support clinical development and manufacturing for its CAR-T candidate NXC-201, which received FDA Breakthrough Therapy Designation in January 2026.
What Firelda Watch includes for Immix Biopharma, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Immix Biopharma, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Immix Biopharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more